Scholarlink

Purpose <p>Graves’ ophthalmopathy (GO) affects up to 40% of patients with Graves’ disease. Identifying biomarkers that predict which patients with Graves’ disease may develop GO or determining which GO patients will respond to conservative treatment is critical for improving targeted management. This study aims to investigate potential circulating miRNAs in serum or plasma that may serve as biomarkers for the diagnosis and prognosis of GO.</p> Methods <p>A systematic literature search was conducted in the MEDLINE, EMBASE, and Cochrane databases. Studies involving human participants with or without GO that assessed miRNA expression levels in serum, plasma, or CD4<sup>+</sup> T cells were deemed eligible for inclusion.</p> Results <p>Eleven studies met the inclusion criteria. A total of 6567 miRNAs were analyzed in the serum, plasma, or CD4<sup>+</sup> T cells of 195 patients. In patients with GO, seven miRNAs were significantly upregulated, while four miRNAs were downregulated. Among GO patients who responded to glucocorticoid treatment, one miRNA was upregulated, and two miRNAs were downregulated. In GO patients resistant to glucocorticoid treatment, one miRNA was significantly downregulated.</p> Conclusion <p>MiRNAs hold promise as biomarkers for the early diagnosis, prognosis, and prediction of response to glucocorticoid therapy in GO patients. There is a correlation between miRNA expression in serum or plasma and the presence, activity, and response to glucocorticoid therapy in GO patients. However, further clinical studies are necessary to validate the predictive value of miRNAs as biomarkers in clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Circulating miRNAs in Graves’ ophthalmopathy: a systematic review

  • 期刊论文

  • 发表日期：

    2025年6月28日

查看全文
  • Evangelia Syrakouli,
  • Georgios Geropoulos,
  • Styliani Laskou,
  • Elissavet Anestiadou,
  • Argyro Syrakouli,
  • Georgios Koimtzis,
  • Vasileios Geropoulos,
  • Dimitrios Giannis,
  • Konstantinos Sapalidis,
  • Kyriakos Psarras

摘要

Purpose

Graves’ ophthalmopathy (GO) affects up to 40% of patients with Graves’ disease. Identifying biomarkers that predict which patients with Graves’ disease may develop GO or determining which GO patients will respond to conservative treatment is critical for improving targeted management. This study aims to investigate potential circulating miRNAs in serum or plasma that may serve as biomarkers for the diagnosis and prognosis of GO.

Methods

A systematic literature search was conducted in the MEDLINE, EMBASE, and Cochrane databases. Studies involving human participants with or without GO that assessed miRNA expression levels in serum, plasma, or CD4+ T cells were deemed eligible for inclusion.

Results

Eleven studies met the inclusion criteria. A total of 6567 miRNAs were analyzed in the serum, plasma, or CD4+ T cells of 195 patients. In patients with GO, seven miRNAs were significantly upregulated, while four miRNAs were downregulated. Among GO patients who responded to glucocorticoid treatment, one miRNA was upregulated, and two miRNAs were downregulated. In GO patients resistant to glucocorticoid treatment, one miRNA was significantly downregulated.

Conclusion

MiRNAs hold promise as biomarkers for the early diagnosis, prognosis, and prediction of response to glucocorticoid therapy in GO patients. There is a correlation between miRNA expression in serum or plasma and the presence, activity, and response to glucocorticoid therapy in GO patients. However, further clinical studies are necessary to validate the predictive value of miRNAs as biomarkers in clinical practice.